It has been extensively reported that overexpression of ABCB1 in cancer cells can confer resistance to chemotherapeutic agents such as paclitaxel, vincristine, colchicine, as well as tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib (Dohse et al., 2006; Hegedus et al., 2009). Here, ABCB1 is linked to cancer.